Metformin and the risk of malignant tumors of digestive system: a mendelian randomization study
Abstract Background Observational studies suggest that metformin may reduce the risk of malignant tumors of the digestive system (MTDS), but these findings are often confounded by bias and unmeasured variables. Recent meta-analyses have questioned these associations, emphasizing the need for robust...
Saved in:
| Main Authors: | Ping Liu, Junqi Xiao, Jinghuang Xiao, Jumei Zhou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-024-01573-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of metformin with risk of digestive tract cancers from a drug target mendelian randomization and cell experiments
by: Yifei Wang, et al.
Published: (2025-05-01) -
Metformin reduces the risk of frailty: evidence from a Mendelian randomization study
by: Tong Chen, et al.
Published: (2025-06-01) -
Metformin and Risks of Aortic Aneurysm and Aortic Dissection: A Mendelian Randomization Study
by: Lei Wang, et al.
Published: (2025-04-01) -
Unravelling the association between metformin and pan-cancers: Mendelian randomization combined with NHANES database analysis
by: Jia-Cheng Xiang, et al.
Published: (2025-03-01) -
Metformin and risk factors for chronic kidney disease in a European population based on Mendelian randomization
by: Xiaopei Liu, et al.
Published: (2025-12-01)